Diagnosis problems of paraneoplastic cerebellar degeneration

Paraneoplastic cerebellar degeneration (PCD) is a rare form of the paraneoplastic neurological syndrome (PNS). PCD is an autoimmune disease of the central nervous system (CNS) affecting the Purkinje cells and possibly other cells of the cerebellum. PCD is characterized by a rapid onset resulting in...

Full description

Bibliographic Details
Main Authors: N.A. Shnaider, V.V. Ezhikova, Yu.A. Dykhno, D.V. Dmitrenko, Yu.S. Panina
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2014-05-01
Series:Неврология, нейропсихиатрия, психосоматика
Subjects:
Online Access:https://nnp.ima-press.net/nnp/article/view/380
_version_ 1797876488903589888
author N.A. Shnaider
V.V. Ezhikova
Yu.A. Dykhno
D.V. Dmitrenko
Yu.S. Panina
author_facet N.A. Shnaider
V.V. Ezhikova
Yu.A. Dykhno
D.V. Dmitrenko
Yu.S. Panina
author_sort N.A. Shnaider
collection DOAJ
description Paraneoplastic cerebellar degeneration (PCD) is a rare form of the paraneoplastic neurological syndrome (PNS). PCD is an autoimmune disease of the central nervous system (CNS) affecting the Purkinje cells and possibly other cells of the cerebellum. PCD is characterized by a rapid onset resulting in disability for a few days or weeks; a slow progredient increase in cerebellar symptomatology is observed less often. PCD develops in 1–3% of cancer patients; its fraction accounts for 25% of all forms of PNS. The mean incidence rate of PCD is about 2 cases per 1,000 cancer patients. PCD develops in patients with cancer of the ovary, uterus and fallopian tubes, with small cell lung cancer and Hodgkin's lymphoma. The incidence rate among females is 3 times higher than that among males. Females aged 50–65 years are most likely to suffer from PCD. PCDs are divided into four main subgroups that differ in terms of prognosis and range of associated antineuronal antibodies. In the last decade, different classes of anti-onconeuronal antibodies associated with PCD have been described; 9 of them have been best studied. Anti-Yo and anti-Hu antibodies are most frequently detected upon PCD. PCD can be also diagnosed without anti-onconeuronal antibodies associated with it or their titer in the blood can be low. Differential diagnosis of PCD is complex and is conducted for a wide range of CNS diseases. No single approach to treating PCD currently exists. Surgical removal of the tumor, the source of production of anti-onconeuronal antigens, followed by radiotherapy and/or chemotherapy, does not solve the problem completely, but may reduce severity of the clinical manifestations of PCD or stabilize the pathological process. This explains the need for rapid and profound search for a tumor in patients suspected with PCD. The authors described a clinical case of an acute debut of PCD in 47-year-old female, 6 months after which, the patient was diagnosed with breast cancer. The problems of PCD diagnosis by neurologists are discussed. The importance of the interdisciplinary approach to diagnosis and follow-up monitoring of patients with this nosology is noted.
first_indexed 2024-04-10T02:03:59Z
format Article
id doaj.art-52500b6bbc8b4dbaaec5d3de6ae16e94
institution Directory Open Access Journal
issn 2074-2711
2310-1342
language Russian
last_indexed 2024-04-10T02:03:59Z
publishDate 2014-05-01
publisher IMA-PRESS LLC
record_format Article
series Неврология, нейропсихиатрия, психосоматика
spelling doaj.art-52500b6bbc8b4dbaaec5d3de6ae16e942023-03-13T08:42:13ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422014-05-0161354310.14412/2074-2711-2014-1-35-43371Diagnosis problems of paraneoplastic cerebellar degenerationN.A. Shnaider0V.V. Ezhikova1Yu.A. Dykhno2D.V. Dmitrenko3Yu.S. Panina4Voyno-Yasenetsky Krasnoyarsk State Medical University, the Ministry of Health of the Russian Federation, Neurological Center of Epileptology, Neurogenetics, and Brain Research of the University Hospital, Krasnoyarsk, RussiKryzhanovsky Krasnoyarsk Regional Cancer Center, Krasnoyarsk, Russiaoyno-Yasenetsky Krasnoyarsk State Medical University, the Ministry of Health of the Russian Federation, Neurological Center of Epileptology, Neurogenetics, and Brain Research of the University Hospital, Krasnoyarsk, RussiaVoyno-Yasenetsky Krasnoyarsk State Medical University, the Ministry of Health of the Russian Federation, Neurological Center of Epileptology, Neurogenetics, and Brain Research of the University Hospital, Krasnoyarsk, RussiaVoyno-Yasenetsky Krasnoyarsk State Medical University, the Ministry of Health of the Russian Federation, Neurological Center of Epileptology, Neurogenetics, and Brain Research of the University Hospital, Krasnoyarsk, RussiaParaneoplastic cerebellar degeneration (PCD) is a rare form of the paraneoplastic neurological syndrome (PNS). PCD is an autoimmune disease of the central nervous system (CNS) affecting the Purkinje cells and possibly other cells of the cerebellum. PCD is characterized by a rapid onset resulting in disability for a few days or weeks; a slow progredient increase in cerebellar symptomatology is observed less often. PCD develops in 1–3% of cancer patients; its fraction accounts for 25% of all forms of PNS. The mean incidence rate of PCD is about 2 cases per 1,000 cancer patients. PCD develops in patients with cancer of the ovary, uterus and fallopian tubes, with small cell lung cancer and Hodgkin's lymphoma. The incidence rate among females is 3 times higher than that among males. Females aged 50–65 years are most likely to suffer from PCD. PCDs are divided into four main subgroups that differ in terms of prognosis and range of associated antineuronal antibodies. In the last decade, different classes of anti-onconeuronal antibodies associated with PCD have been described; 9 of them have been best studied. Anti-Yo and anti-Hu antibodies are most frequently detected upon PCD. PCD can be also diagnosed without anti-onconeuronal antibodies associated with it or their titer in the blood can be low. Differential diagnosis of PCD is complex and is conducted for a wide range of CNS diseases. No single approach to treating PCD currently exists. Surgical removal of the tumor, the source of production of anti-onconeuronal antigens, followed by radiotherapy and/or chemotherapy, does not solve the problem completely, but may reduce severity of the clinical manifestations of PCD or stabilize the pathological process. This explains the need for rapid and profound search for a tumor in patients suspected with PCD. The authors described a clinical case of an acute debut of PCD in 47-year-old female, 6 months after which, the patient was diagnosed with breast cancer. The problems of PCD diagnosis by neurologists are discussed. The importance of the interdisciplinary approach to diagnosis and follow-up monitoring of patients with this nosology is noted.https://nnp.ima-press.net/nnp/article/view/380paraneoplastic cerebellar degenerationparaneoplastic neurological syndromediagnosiscanceranti-onconeuronal antibodies.
spellingShingle N.A. Shnaider
V.V. Ezhikova
Yu.A. Dykhno
D.V. Dmitrenko
Yu.S. Panina
Diagnosis problems of paraneoplastic cerebellar degeneration
Неврология, нейропсихиатрия, психосоматика
paraneoplastic cerebellar degeneration
paraneoplastic neurological syndrome
diagnosis
cancer
anti-onconeuronal antibodies.
title Diagnosis problems of paraneoplastic cerebellar degeneration
title_full Diagnosis problems of paraneoplastic cerebellar degeneration
title_fullStr Diagnosis problems of paraneoplastic cerebellar degeneration
title_full_unstemmed Diagnosis problems of paraneoplastic cerebellar degeneration
title_short Diagnosis problems of paraneoplastic cerebellar degeneration
title_sort diagnosis problems of paraneoplastic cerebellar degeneration
topic paraneoplastic cerebellar degeneration
paraneoplastic neurological syndrome
diagnosis
cancer
anti-onconeuronal antibodies.
url https://nnp.ima-press.net/nnp/article/view/380
work_keys_str_mv AT nashnaider diagnosisproblemsofparaneoplasticcerebellardegeneration
AT vvezhikova diagnosisproblemsofparaneoplasticcerebellardegeneration
AT yuadykhno diagnosisproblemsofparaneoplasticcerebellardegeneration
AT dvdmitrenko diagnosisproblemsofparaneoplasticcerebellardegeneration
AT yuspanina diagnosisproblemsofparaneoplasticcerebellardegeneration